Hyperhidrosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hyperhidrosis. 20 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
20
Active US patents
68/100
Avg vulnerability
—
Annual revenue covered

Originators in Hyperhidrosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Kaken Pharmaceutical 20 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hyperhidrosis. Each bar = one year. Y-axis scaled to peak year (15 patents).

1
26
1
27
15
34
1
37
2
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ecclock
SOFPIRONIUM BROMIDE
 Kaken Pharmaceutical 20 68 — 2026-11-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8628759 Ecclock method of use 93 2026-11-13
9492429 Ecclock method of use 75 2034-03-14
9895350 Ecclock method of use 75 2034-03-14
9220707 Ecclock method of use 75 2034-03-14
10383846 Ecclock method of use 75 2034-03-14
10947192 Ecclock method of use 75 2034-05-22
11026919 Ecclock method of use 75 2034-05-22
10959983 Ecclock method of use 75 2034-05-22
10961191 Ecclock method of use 75 2034-05-22
10952990 Ecclock method of use 75 2034-05-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11566000 Ecclock composition of matter 17 2040-05-22
11584715 Ecclock composition of matter 17 2040-05-22
8147809 Ecclock composition of matter 35 2027-03-26
11123325 Ecclock method of use 75 2037-07-20
11034652 Ecclock method of use 75 2034-05-22
10947192 Ecclock method of use 75 2034-05-22
11026919 Ecclock method of use 75 2034-05-22
10959983 Ecclock method of use 75 2034-05-22
10961191 Ecclock method of use 75 2034-05-22
10952990 Ecclock method of use 75 2034-05-22

Related